Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | ATM |
Variant | P1069fs |
Impact List | frameshift |
Protein Effect | loss of function - predicted |
Gene Variant Descriptions | ATM P1069fs results in a change in the amino acid sequence of the Atm protein beginning at aa 1069 of 3056, likely resulting in premature truncation of the functional protein (UniProt.org). P1069fs has not been characterized, however, due to the effects of other truncation mutations downstream of P1069 (PMID: 16603769), is predicted to lead to a loss of Atm protein function. |
Associated Drug Resistance | |
Category Variants Paths |
ATM mutant ATM inact mut ATM P1069fs |
Transcript | NM_000051.4 |
gDNA | chr11:g.(108272772_108272773) |
cDNA | c.(3205_3204) |
Protein | p.P1069fs |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
XM_011542840.4 | chr11:g.(108272772_108272773) | c.(3205_3204) | p.P1069fs | RefSeq | GRCh38/hg38 |
XM_006718843.4 | chr11:g.(108272772_108272773) | c.(3205_3204) | p.P1069fs | RefSeq | GRCh38/hg38 |
XM_011542840.3 | chr11:g.(108272772_108272773) | c.(3205_3204) | p.P1069fs | RefSeq | GRCh38/hg38 |
NM_001351834.2 | chr11:g.(108272772_108272773) | c.(3205_3204) | p.P1069fs | RefSeq | GRCh38/hg38 |
XM_047426976.1 | chr11:g.(108272772_108272773) | c.(3205_3204) | p.P1069fs | RefSeq | GRCh38/hg38 |
NM_000051.3 | chr11:g.(108272772_108272773) | c.(3205_3204) | p.P1069fs | RefSeq | GRCh38/hg38 |
XM_017017790.2 | chr11:g.(108272772_108272773) | c.(3205_3204) | p.P1069fs | RefSeq | GRCh38/hg38 |
XM_047426975.1 | chr11:g.(108272772_108272773) | c.(3205_3204) | p.P1069fs | RefSeq | GRCh38/hg38 |
XM_017017790.3 | chr11:g.(108272772_108272773) | c.(3205_3204) | p.P1069fs | RefSeq | GRCh38/hg38 |
XM_017017789.2 | chr11:g.(108272772_108272773) | c.(3205_3204) | p.P1069fs | RefSeq | GRCh38/hg38 |
XM_017017791.1 | chr11:g.(108272772_108272773) | c.(3205_3204) | p.P1069fs | RefSeq | GRCh38/hg38 |
XM_011542843.2 | chr11:g.(108272772_108272773) | c.(3205_3204) | p.P1069fs | RefSeq | GRCh38/hg38 |
XM_006718843.5 | chr11:g.(108272772_108272773) | c.(3205_3204) | p.P1069fs | RefSeq | GRCh38/hg38 |
XM_017017792.2 | chr11:g.(108272772_108272773) | c.(3205_3204) | p.P1069fs | RefSeq | GRCh38/hg38 |
XM_011542843.3 | chr11:g.(108272772_108272773) | c.(3205_3204) | p.P1069fs | RefSeq | GRCh38/hg38 |
NM_001351834.1 | chr11:g.(108272772_108272773) | c.(3205_3204) | p.P1069fs | RefSeq | GRCh38/hg38 |
XM_047426981.1 | chr11:g.(108272772_108272773) | c.(3205_3204) | p.P1069fs | RefSeq | GRCh38/hg38 |
XM_005271562.6 | chr11:g.(108272772_108272773) | c.(3205_3204) | p.P1069fs | RefSeq | GRCh38/hg38 |
XM_005271562.5 | chr11:g.(108272772_108272773) | c.(3205_3204) | p.P1069fs | RefSeq | GRCh38/hg38 |
NM_000051.4 | chr11:g.(108272772_108272773) | c.(3205_3204) | p.P1069fs | RefSeq | GRCh38/hg38 |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
ATM P1069fs ATM LOH | salivary gland adenoid cystic carcinoma | predicted - sensitive | Ceralasertib + Olaparib | Case Reports/Case Series | Actionable | In a Phase II trial (OLAPCO), Ceralasertib (AZD6738) and Lynparza (olaparib) combination treatment resulted in an ongoing 22% reduction in target lesions in a patient with adenoid cystic carcinoma of minor salivary gland harboring germline ATM P1069fs with accompanying loss of heterozygosity (LOH), who remained on treatment for over 26 months (PMID: 34527850; NCT02576444). | 34527850 |